Teva Pharmaceutical Industries SG&A Expenses 2010-2024 | TEVA
Teva Pharmaceutical Industries sg&a expenses for the twelve months ending September 30, 2024 were $3.651B, a 6.38% increase year-over-year.
- Teva Pharmaceutical Industries annual sg&a expenses for 2023 were $3.498B, a 1.54% increase from 2022.
- Teva Pharmaceutical Industries annual sg&a expenses for 2022 were $3.445B, a 2.35% decline from 2021.
- Teva Pharmaceutical Industries annual sg&a expenses for 2021 were $3.528B, a 3.9% decline from 2020.